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Abstract 
Albumin, a protein that when found in urine, is an early indicator of Chronic Kidney Disease 
(CKD). Genetic contributions have been shown to illustrate the gene-environment interactions 
that may lead to CKD in an individual; however, few studies have highlighted the interaction 
between responses of gene variations associated with the risk of increased albumin in young 
adults.  This study’s purpose is to evaluate the hypothesis that candidate genes are related to 
microalbuminuria in young adults of the third wave of the National Longitudinal Study of 
Adolescent Health (Add Health Wave III). This longitudinal study includes an assessment of 
various candidate genes typically reported to be associated with behavioral differences in 
individuals and urinalysis results collected from a large population of young adults. The data set 
also contains a twin & sibling sample that is analyzed to find an association between various 
genes while controlling for family relativity. Findings include an association found within the 
sibling sample between women and single nucleotide polymorphisms (SNPs), rs892413 & 
rs4950. A better understanding of genetic factors associated with kidney functioning in this age 
group could improve our knowledge of the complex genetics of kidney function as well as guide 
prevention and intervention methods. 
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Chapter 1: Introduction 
“Chronic Kidney Disease (CKD) is a condition in which your kidneys are damaged and 
cannot filter blood as well as healthy kidneys” (Center for Disease Control and Prevention, 
2014). When kidneys are unable to filter waste, waste from blood remains in the body which can 
initiate many health problems. People living with early CKD rarely notice symptoms or feel ill 
and CKD can only be diagnosed through specific blood and urine testing (Center for Disease 
Control and Prevention, 2014). The progression of kidney disease can be slowed down or 
prevented through early detection and treatment, but many adults are not screened for kidney 
disease until it is in its advanced stages (National Kidney Foundation, 2016). Complications 
associated with Chronic Kidney Disease include high blood pressure, anemia, weak bones, poor 
nutritional health and nerve damage (National Kidney Foundation, 2016). Nephrologists, or 
Kidney Specialists, classify Chronic Kidney Disease by five stages according to the rate of 
Glomerular Filtration (GFR) (“Chronic Kidney Disease,” n.d.). GFR is the rate at which kidneys 
filter waste and decreases in an individual as CKD progresses (“Chronic Kidney Disease,” n.d.). 
Stage 5 CKD ultimately leads to necessary dialysis or kidney transplant in order to avoid death 
(National Kidney Foundation, 2016). Those at higher risk of CKD include adults over 60, with 
diabetes, high blood pressure, cardiovascular disease or family history of kidney failure, and 
African American and Hispanic ethnicities (National Kidney Foundation, 2016). According to 
the National Kidney Foundation (2016), 26 million adults in the United States have CKD and 1 
in 3 American adults are currently at risk for developing kidney disease.  
As the prevalence of diseases associated with overweight and obesity increase in 
adolescents, early Chronic Kidney Disease (CKD) prevalence has increased in adolescents in the 
past 20 years (Ferris et al, 2007). In the past 30 years in the United States, obesity has “doubled 
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in children and quadrupled in adolescents.” (Centers for Disease Control & Prevention, 2015). 
From 1999-2010, National Health and Nutrition and Examination Survey (NHANES) reported 
that among children and adolescents in the U.S population, one-third were overweight or obese. 
Of U.S residents aged 2-19, adolescents (ages 15-19) were more likely than younger children 
(ages 2-4) to be overweight or obese (“Chronic Kidney Disease Surveillance System,” n.d.). 
Factors associated with being overweight or obese increase the rates of hypertension, diabetes 
and other metabolic disease in adolescents (Ferris et al, 2007). According to the CDC, between 
2011 and 2013 adolescents (ages 18-21) had the highest adjusted incidence of treated End-Stage 
Renal Disease (ESRD) of those under 22 years of age at 30 cases per million persons. (“Chronic 
Kidney Disease Surveillance System,” n.d.). 
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Chapter 2: Background 
While the risk of chronic kidney disease is increasing in the population due to higher 
rates of metabolic diseases, the understanding of the underlying risk factors associated with the 
progression of renal disease is still complex. The development of CKD varies in individuals 
based on ethnic background, lifestyle factors, and genetic factors (Kottgen et al, 2010). Risk 
factors such as hypertension or diabetes that may contribute to the progression of kidney disease 
can be prevented by moderate exercise, a healthier diet, and weight reduction (Office of Disease 
Prevention and Health Promotion, 2017). Behavior modifications to lifestyle choices can 
significantly reduce the progression of CKD, but some populations, such as Hispanics or African 
Americans, are disproportionately disadvantaged (Office of Disease Prevention and Health 
Promotion, 2017). Modifiable factors within an individual’s immediate environment have a 
significant influence on the progression of CKD, but genetic determinants also have a large 
influence on the development of CKD (Office of Disease Prevention and Health Promotion, 
2017). While it is difficult to indicate one specific gene x environment interaction with the risk 
of CKD, many studies have characterized chronic kidney disease as having multiple 
environmental exposures that could influence the many biological processes involved with the 
progression of CKD (Bruce et al., 2009). Exposure to environmental, social or behavioral 
factors, such as depression, anxiety, stress, economic deprivation, discrimination, smoking, and 
drug use can adversely affect the etiology of CKD and initiate responses in the nervous or 
vascular system that may increase the risk for progression of CKD (Bruce et.al, 2009). 
Responses that effect blood pressure, heart rate, and vascular reactivity are thought to be 
associated with alterations in the sympathetic/autonomic nervous system and may provide an 
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etiological link between stress, hypertension and CKD, particularly in high risk populations 
(Bruce et al., 2009) 
Identifying gene variants associated with the risk of common diseases has been difficult, 
but recent genome-wide association studies (GWAS) evaluation of common diseases have 
assessed common diseases and improved our overall knowledge of genetic influences (Melzer et 
al, 2008). Rather than associating genetic factors to the disease, many studies have begun to 
approach disease etiology by studying the association of gene variation and gene expression 
(Melzer et al, 2008). Identifying genetic variations that influence serum or plasma protein levels 
of common disease are more likely to be more associated directly to the progression of a specific 
disease (Melzer et al, 2008). Although there are multiple factors that influence serum and plasma 
protein levels, the role that genetic variation has on differences in mRNA transcription and the 
MRNA translation to protein that follows mRNA transcription could be more implicative of an 
association of a genetic variation and the resulting expression of a disease (Melzer et al, 2008). It 
is often unknown whether protein levels are involved in the disease progress or a result of the 
disease process and identification of gene variants associated with serum and plasma proteins 
could improve the knowledge on these relationships (Melzer et al, 2008).  
Multiple GWAS have already demonstrated the relationship between some specific 
genetic variants, estimated glomerular filtration rate (eGFR), CKD and End Stage Renal Disease 
(ESRD). Markers of Chronic Kidney Disease, such as serum creatinine (SCr), eGFR, and/or 
albumin, have been found to account for 29% to 33% of heritability estimates (Gudbjartsson et 
al, 2010). Recent GWAS have found significant associations between estimated glomerular 
filtration rate based on serum creatinine (eGFRcrea) and genes at three loci: UMOD, 
SHROOM3, and GATM-SPATA5L1. Gudbjartsson and colleagues (2010) also found significant 
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associations in an Icelandic adult population by analyzing eGFR based on cystatin C (eGFRcys), 
another measure of kidney function, and genes at two loci: CST9 and STC1 (Gudbjartsson et al, 
2010). Additional genes found associated with renal function and Chronic Kidney Disease 
include: LASS2, GCKR, ALMS1, TFDP2, DAB2, SLC34A1, VEGFKA, PRKAG2, PIP5K1B, 
ATXN2, DACH1, UBE2Q2, and SLC7A9 (Kottgen et al, 2010). Kottgen and collegues (2010) 
also found 7 genes suspected to affect production and secretion of the creatinine protein-CPS1, 
SLC22A2, TMEM60, WDR37, SLC6A13, WDR72, and BCAS3.  Other significant associations 
have also been shown in African Americans and genes associated with albuminuria located at 
two loci: MYH9 & APOL1 (Freedman et al, 2009). Risk alleles common in African Americans 
demonstrate the genetic and environment differences between individuals that are deserving of 
additional study (Friedman et al, 2011). Other loci found to be considered associated with 
genetic kidney diseases are ELMO1, NPHS1, NPHS2, INF2, LAMB2, PLCE1, ACTN4, TRPC6, 
WT1, PKHD1, and NPHP1-NPHP9 (Hildebrandt, 2010). 
Genetic technology has increased knowledge of diagnosis, classification, pathogenesis, 
and personalized therapy surrounding kidney disease (‘Inherited Kidney Diseases’, 2014). 
Increased susceptibility to CKD can be caused by a combination of environmental factors, genes, 
and their interactions (Satko et al, 2005). Even with the most common causes of kidney disease 
being diabetes and high blood pressure, genetic factors increase the varying degrees of 
progression of chronic kidney disease in individuals (Eikmans et al, 2006). Genetic variants 
found in association with the risk of CKD can be identified in genes for heart and vascular 
diseases, glomerulonephritis, diabetes, inherited renal diseases or genes that maintain ionic 
balance (Rosas, 2012). According to Eikmans and colleagues (2006), genetic components of 
kidney disease could be initiated from a single gene mutation which could result in interrupting 
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the function of a corresponding protein; or several genetic factors could mutate only in the 
presence of other systemic diseases, such as hypertension or diabetes. The etiology surrounding 
many kidney diseases has been revealed to be due to single-gene defects and are associated with 
risk alleles (variants of genetic material related to an increased risk of developing a certain 
disease) (‘Inherited Kidney Diseases’, 2014). Single- gene disorders, or monogenic diseases, 
occur when a mutation of a single gene (out of more than 25,000 genes) is the cause of a disease. 
A polygenic disorder occurs when multiple genes mutate simultaneously and result in a disease 
(Hildebrandt, 2010). According to Hildebrandt (2010), a mutation within a monogenic recessive 
gene has an increased power to “fully penetrate” or manifest into CKD during childhood or 
adolescence and leave little room for environmental influences. When compared to monogenic 
recessive genes, monogenic dominant genes may not fully manifest into the outcome of CKD 
until adulthood and may vary according to generation or organ involvement (Hildebrandt, 2010). 
In contrast, multiple risk alleles associated with polygenic diseases typically manifest during 
adulthood and they leave more room for environmental influences since they show less 
heritability within an individual (Hildebrandt, 2010). Regardless of where the gene is expressed, 
the relationship between progression of renal disease and genetic expression is obvious, and 
identifying additional genetic variants that could impact the progression of renal function may 
increase the understanding of the etiology of CKD in adolescents (Eikmans et al, 2006). 
Detection of CKD early can prevent the progression of the disease, but early detection 
can be difficult due to signs and symptoms of CKD being overlooked until later stages of CKD 
(“Chronic Kidney Disease,” n.d.). Albumin, a protein sometimes found in the urine, has well 
documented cases of understanding kidney disease in the older population, including being a 
marker for early diagnosis of Cardiovascular Disease (CVD) in the short term and End-Stage 
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Renal Disease (ESRD) in the long term (National Kidney Foundation, 2016). In individuals with 
or without diabetes, testing for albumin in the blood serum may be the first step to detecting 
undiagnosed CKD (Jong et al, 2006). Albumin is present normally in the urine but when the 
level is elevated to between 30-300mg/dL, it is an early indicator of a progressive loss of renal 
function. Elevation of albumin above 30mg/dL, or microalbuminuria, is an early sign of 
progressive cardiovascular and renal disease and albumin levels above 300mg/dL usually 
indicated that the person is in stage 3 or 4 CKD (Jong et al, 2006).  
The interaction of specific genetic alleles with albumin expression can be important in 
understanding additional gene and environment interactions. The purpose of this study is to 
assess the association between candidate genes and urinalysis results collected from a large 
cohort. We will evaluate the overall association of various candidate genes and urinalysis results, 
the association of candidate genes and urinalysis results between genders, and the association of 
candidate genes and urinalysis results when controlling for other risk factors related to Chronic 
Kidney Disease.   
A better understanding of additional genetic variations associated with kidney 
functioning in adolescents could improve our knowledge of the complex biological pathways 
effecting the decrease in kidney function as well as guide prevention and intervention methods. 
Research Questions 
The research questions that will be evaluated in this study are as follows: 
1. Is there a significant association between candidate genes related to psychosocial & 
behavioral traits and elevated albumin in adolescents? 
2. Is there a significant association between candidate genes related to psychosocial & 
behavioral traits and elevated albumin when separated by gender? 
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3. Are the various candidate genes related to psychosocial & behavioral traits significant 
predictors of elevated albumin when controlling for additional risk factors of Chronic 
Kidney Disease? 
Hypotheses 
The hypotheses for research question #1 to be evaluated in this study are: 
  H1o: There is no significant association between candidate genes related to psychosocial 
& behavioral traits and elevated albumin found in adolescents (ρ=0) 
  H1a: There is a significant association between candidate genes and elevated albumin 
found in adolescents (ρ≠0) 
   
The hypothesis for research question #2 to be evaluated in this study are: 
  H2o: There is no significant association between candidate genes and elevated albumin 
when separated by gender (ρM=0) 
  H2a: There is a significant association between candidate genes and elevated albumin 
when separated by gender (ρ≠0) 
 
The hypothesis for research question #3 to be evaluated in this study are: 
  H3o: Each candidate gene is not a significant predictor of elevated albumin when 
controlling for additional risk factors (ρ=0) 
  H3a: Each candidate genes is a significant predictor of elevated albumin when controlling 
for additional risk factors (ρ≠0) 
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Chapter 3: Methods 
Study population 
The purpose of this retrospective cohort study is to assess the hypothesis that candidate 
genetic variants are associated with albuminuria in young adults who participated in the third 
wave of the National Longitudinal Study of Adolescent Health (Add Health Wave III). This 
study will include an assessment of urinalysis and DNA samples collected from a large 
population of young adults, which is not commonly studied concerning progressive CKD.   
The National Longitudinal Study of Adolescent Health, lasting over 10 years, is the 
largest nationally representative data set to also include a urinalysis for most of its participants. 
The study, initiated in 1994, consists of in school or in home interviews between 4 different 
waves. The participants of the study are part of a cohort or young adults aged 18 to 26 years. The 
study used multistage, stratified, clustered sampling within schools to ensure the population was 
representative of U.S. adolescents. After randomization, students were stratified by grade and 
sex, and selected out of 200 from each school pair. In Wave 3, conducted in 2001-2002, there 
was 77.4% response rate of participants from Wave 1. Wave 3 consisted of 15,197 participants 
from Wave 1, many of which were in between the ages of 18-26 at the time of Wave 3. During 
Wave 3, 1,507 romantic partners were also interviewed. Biomarkers collected during this wave 
included: height and weight used to determine BMI, urine sample collection in order to 
determine STI status, and genetic buccal cell DNA to compare twin and sibling data. 
 
Urinalysis data and specimen collection 
Respondents completed a survey including responses on demographics, education, 
socioeconomic status, height, weight, medical conditions, and smoking history. Height and 
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weight was measured by field workers and BMI was calculated as weight in kilograms divided 
by height in meters squared (kg/m²). 12, 566 urine samples were initially available. Samples 
were discarded if they were improperly shipped, not kept at the correct temperature, or 
insufficient (n=390). All other samples (n=12,176) underwent urinalysis. Urine samples from 
romantic partners were excluded, leaving the total sample for urinalysis at 10,867 respondents. 
Urinalysis results were defined as positive for albumin when >30 mg/dl (0.30 g/L). 
Macroalbuminuria and microalbuminuria measurements were collected in a subset of 
respondents, chosen by BMI to maximize statistical power. Of the 10,868 urinalysis results from 
Wave I participants (romantic partners excluded), 2000 samples were randomly selected from 
three BMI groups (n=6000): ≤ 28, 28.01 to 29.99, ≥ 30 kg/m (Smolen & Hewitt, 2009). To limit 
false-positive albuminuria values, exclusions were applied based on the PREVEND study by 
excluding pregnant (n=219) women and those with >75 WBC/ul (n=1,026) or >50 RBC/ul 
(n=599) (Verhave et al, 2004). “Exclusion criteria was applied to rule out microalbuminuria 
associated with pregnancy, urinary tract infections or any blood disorders not related to kidney 
disease; therefore they differ from definitions that typically describe urinalysis findings, with the 
exception of glycosuria.” (Verhave et al, 2004). After applying exclusion criteria, urine results 
were merged with the genetic sample yielding 1,210 respondents that were included in the 
analysis for albuminuria. 
Additional measures in this study include race, age, gender, education and having 
smoked at least one cigarette within the past 30d. History of hypertension and diabetes were self-
reported.   
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DNA data and specimen collection 
Respondents who were selected for DNA sample were asked to insert one sterile 
cytology brush into the mouth and rub the cheeks and gums for 20 seconds to collect buccal 
cells. Test tubes were labeled for each respondent and packaged for shipment with ice packs to 
maintain a temperature of 4°C until received at the University of Arizona laboratory for DNA 
extraction. Specimens were later transferred to the University of Colorado for genetic typing and 
analysis (Smolen & Hewitt, 2009). 
To genotype DNA for five candidate polymorphisms, saliva samples were collected from 
full siblings or twins. “These candidate genes have been reported to be associated with individual 
differences in behavior related to mental health; are reported to be functional, exonic, in 
promoter regions, or affect gene expression; are expressed in the brain; and have prima facie 
involvement in neurotransmission” (Smolen & Hewitt, 2009). The candidates are the dopamine 
transporter (DAT1), the dopamine D4 receptor (DRD4), the serotonin transporter (5HTT), 
monoamine oxidase A (MAOA), and the dopamine D2 receptor (DRD2). The following 
additional genotypes were also available for Wave III respondents: CYP2A6, rs2304297, 
rs892413, rs4950, and rs13280604. The candidate genes evaluated in this study are introduced in 
detail below: 
Dopamine Transporter (locus symbol: SLC6A3) - Variable Name: DAT1 A & B 
The dopamine active transporter 1 gene, mediates the reuptake of dopamine from the 
synapse and is shown to be associated with expression of the DAT protein in lymphocytes and in 
human striatum (“DAT1 Gene,” n.d.). DAT1 contains variable number tandem repeats (VNTRs), 
where specific locations in the gene can have multiple numbers of repeats and can cause 
individual differences in expression of protein levels. VNTRs in the DAT1 gene have been 
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reported to be associated with attention deficit/hyperactivity disorder (ADHD), bipolar disorder, 
and antidepressant use (“DAT1 Gene,” n.d.). Allelic sequences within this study to be evaluated 
per the DAT1 gene include 11R 10R, 7R, 8R, and 9R as reported individually. 
Dopamine D4 Receptor (DRD4) - Variable Name: DRD4 A & B 
The dopamine D4 receptor gene, encodes for a D4 subtype which is a G-protein couple 
receptor that inhibits adenylyl cyclase (“DRD4 Gene-Protein Coding,”n.d.). The dopamine D4 
receptor “is a target for drugs that treat schizophrenia and Parkinson disease and mutations 
within this gene have been related to many behavioral expressions such as autonomic nervous 
system dysfunction, ADHD, and the personality trait of novelty seeking” (“DRD4 Gene-Protein 
Coding,”n.d.). Allelic sequences within this study to be evaluated per the DRD4 gene include 
10R, 9R, 8R, 7R, 6R, 5R, 4R, 3R, and 2R as reported individually. 
Serotonin Transporter (5-HTT, locus symbol: SLC6A4) – Variable Name: HTTLPR A & B 
The serotonin transporter encodes for a protein which is responsible for the reuptake of 
serotonin into the presynaptic cell after being released into the synaptic cleft to signal the 
adjacent neuron (“5-HTT:The Depression Gene,"n.d.). Alleles of the 5-HTT gene are either short 
(S) or long (L) , and encode for less or more of a protein according to the length of the allele. 
Variations of the serotonin transporter has shown to be associated with anxiety related 
personality traits, risk of developing depression, alcoholism or suicidal behavior (“5-HTT:The 
Depression Gene,"n.d.). Recent studies of Argentinean adolescents have found an association 
between the polymorphism of the serotonin transporter and being overweight (Fuemmeler, 
2009). 
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Monoamine Oxidase- A promoter (MAOA-uVNTR) – Variable Name: MAOA_VA & 
MAOA_VB 
The product of gene Monoamine Oxidase-A plays an important role in the degradation of 
neurotransmitters such as serotonin, norepinephrine, and dopamine (Brummett et al, 2007). 
MAOA expression has been related to psychological and physical measures and individuals with 
less active MAOA-uVNTR alleles have found to be at increased risk for depressive symptoms 
and poor sleep (Brummett et al, 2007). Allelic sequences within this study to be evaluated per the 
MAOA-uVNTR gene include 5R, 4R, 3.5R, 3R and 2R as reported individually. 
Dopamine D2 Receptor (Taq1A) – Variable Name: DRD2 
       The dopamine D2 receptor gene contains multiple variants which include single nucleotide 
polymorphisms (SNPs), di-nucleotide repeats, and restriction endonuclease sites in coding and 
non-coding regions (Pohjalainen et al, 1998). Alleles associated with the dopamine D2 receptor 
gene are found to be associated with a reduced number of dopamine binding sites, which can 
play a role in addictive behaviors such as alcoholism, smoking, and certain neuropsychiatric 
disorders (Pohjalainen et al, 1998). DRD2 expression has also been found to be associated with 
high blood pressure and protective effects in human renal proximal tubule cells (Pohjalainen et 
al, 1998). This association suggest that carriers of this SNP may be prone to chronic renal disease 
and high blood pressure (Pohjalainen et al, 1998). 
Cytochrome P450 (CYP2A6) - Variable Name: CYP2A6B 
         The cytochrome P450 2A6 is the main catalyst of the oxidation of nicotine and continine 
(“CYP2A6 Gene-Protein Coding,”n.d.). CYP2A6 encodes for a member of the cytochrome P450 
superfamily of enzymes (“CYP2A6 Gene-Protein Coding,”n.d.). Cyctochrome proteins are 
found to be associated with the metabolism and synthesis of various drugs, cholesterols, steroids, 
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and other lipids (“CYP2A6 Gene-Protein Coding,”n.d.). Individuals containing a certain allelic 
variant of CYP2A6 have shown to have a poorly metabolize coumarin or nicotine and is 
associated with reduced number of cigarettes smoked (“CYP2A6 Gene-Protein Coding,”n.d.). 
Neuronal nicotinic cholinergic Receptors (nAChRs) 
          Four receptors have been identified within the CHRNA6 & CHRNB3 genes of the 
nAChRs family. They are expressed in cell bodies and nerve terminal within the brain where 
they regulate the release of neurotransmitters such as glutamate, GABA, serotonin, 
norepinephrine, and dopamine (”CHRNB3 Gene-Protein Coding,”n.d.). nAChRs are typically 
active by acetycholine, but nicotine and other compounds have been found to affect the function 
of these specific receptors, at low concentrations (”CHRNB3 Gene-Protein Coding,”n.d.). 
Genome wide studies have shown that variations of these receptors are related to the likelihood 
and severity of nicotine dependence (”CHRNB3 Gene-Protein Coding,”n.d.). A total of two 
single nucleotide polymorphisms (SNPs) has been genotyped for each cholinergic receptor, 
CHRNA6 & CHRNB3, respectively (”CHRNB3 Gene-Protein Coding,”n.d.). For subunit 
nAChR alpha-6 (CHRNA6), SNPs include rs2304297 (variable name=s000001) and rs892413 
(variable name=s000002). For subunit nAChR beta-3 (CHRNB3), SNPs include rs4950 (variable 
name=s000003) and rs13280604 (variable name=s000004).  
 
Hypothesis 1 Analytical Methods 
Frequencies, percentages, or means with standard errors (SE) were included as 
descriptive statistics for demographics, health characteristics, and urinalysis results. For 
independent samples, a Pearson Chi-squared test will be calculated for each candidate gene to 
test the hypothesis that various gene types are associated with microalbuminuria (albumin >30 
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mg/dl). The Pearson Chi-Squared test is calculated by using frequencies observed within 
categorical variables and frequencies expected within those categorical variables (Fields, p.690). 
Fisher’s exact test will also be used to compute the exact probability of the chi-squared statistic 
and its accuracy when sample sizes are too small (Fields, p.688). Because the genetic sample 
includes families that consist of twins and full or half siblings, a repeated measures model will be 
used to control for the association of family relativity. Therefore, to effectively test the 
association between the gene variant and albuminuria rather than the association within the 
family, a test statistic from the repeated measurement model will be used to accurately analyze 
the association. Associations will be considered significant if the p-value is less than 0.05. If the 
p-value is less than 0.05, the null hypothesis will be rejected. Rejecting the null hypothesis will 
indicate that the candidate gene is associated with microalbuminuria. Frequencies and regression 
models will be performed by using SPSS 23 and SAS 9.4. 
 
Hypothesis 2 Analytical Methods 
The Pearson Chi-squared test will be calculated within the independent samples 
population for each gender along with each candidate gene to test the hypothesis that various 
gene types are associated with microalbuminuria (albumin >30 mg/dl). Fisher’s exact test will be 
used to compute a stronger more accurate probability of the chi-squared statistic when the 
sample size is too small. The repeated measures model will be used in the sibling & twin sample 
to test associations while controlling for family relativity. Associations will be considered 
significant if the p-value is less than 0.05. If the p-value is less than 0.05, the null hypothesis will 
be rejected. Rejecting the null hypothesis will indicate that candidate genes within genders are 
16 
 
associated with microalbuminuria. The Pearson Chi-Squared test and repeated measures models 
will be performed using SPSS 23 and SAS 9.4. 
 
Hypothesis 3 Analytical Methods 
Gene variants found to be significantly associated from the Pearson Chi-Squared test 
analysis will be used for evaluation in the final multilinear model. Logistic regression will be 
used to assess the association of significant genetic variations with albuminuria as well as race, 
sex, Wave III BMI, diabetes, hypertension, and smoking. The repeated measures model will be 
used in the sibling & twin sample to test for associations while controlling for family relativity. 
Variables associated with albuminuria in univariate analysis or that influenced the association 
between DNA types and albuminuria will be considered significant if the p-value is less than 
0.05. Rejecting the null hypothesis will indicate that various candidate genes are associated with 
microalbuminuria when controlling for other risk factors. Multiplicative interactions of BMI with 
sex and race will be explored using multilinear regression. Logistic models will be analyzed 
using SPSS 23 and SAS 9.4. 
 
Limitations 
There are several limitations in this study due to data availability and data collection. 
“Kidney Disease cannot be assessed using a single urine specimen, and could be subject to 
random variation in measures of proteinuria due to prolonged standing or exercise” (Ferris et al, 
2007). This study was not able to use urinalysis samples collected over a time-period to show 
steady albumin levels within respondents. This study also lacked the use of an albumin-to-
creatinine measurement which is clinically preferred for diagnosis of kidney disease; however, 
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“single-measure albuminuria does reflect a chronic condition in 63% of the general population” 
(Ferris et al, 2007). Collection of urine for urinalysis samples was collected by respondents at 
any time of the day, whereas first-morning midstream urine is more specific for albuminuria and 
urinalysis  in clinical settings (Ferris et al, 2007). This study utilized self-reported hypertension 
and diabetes which could indicate undiagnosed or untreated diabetes but did not include clinical 
factors such as measured blood pressure, serum creatinine, or medication use (Ferris et al, 2007).  
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Chapter 4: Results 
The Add health respondents for whom urinalysis (n=10,226) and macroalbumin and 
microalbumin (n=6,306) were analyzed are similar to the overall Add Health Wave III 
respondents (n=15,197) with respect to age, education, diabetes, hypertension, and smoking (see 
Table 1). 
In Add health respondents for whom genetic samples were analyzed along with 
macroalbumin and microalbumin (n=1,210), the measured mean for macroalbumin was 12.78 
mg/dL (range 0.1-5567.20) and 9.87 mg/dL (range 0.001-7641.05) for microalbumin. 
Microalbuminuria was prevalent among 4% or respondents with a macroalbumin measurement 
(n=48), while microalbumin was present among 6.3% of respondents with a microalbumin 
measurement (n=76). With the exception of BMI, those with or without macroalbumin or 
microalbumin measurements were not different among many characteristics, although those with 
microalbuminuria had consistently higher representations of hypertension and smoking. BMI 
was higher among those with microalbumin in the highest BMI category (>35), which is 
consistent with recent findings (See Tables 2 & 3). 
The respondents included in the independent sample (n=578) were analyzed using a 
Pearson Chi-Squared test and a Fisher’s Exact test when applicable, while the sibling & twin 
sample (n=1,210) were analyzed using a repeated measurements model.  
Hypothesis 1 Results 
Gene variants to be found significantly associated (p>0.05) with microalbuminuria in the 
independent sample included Cytochrome P450 2A6-allele B (variable name: CYP2A6B), 
rs2304297- allele A (variable name: S000001A), rs2304297- allele B (variable name: 
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S000001B), rs892413- allele A (variable name: S000002A), rs892413- allele B (variable name: 
S000002B), rs4950- allele B (variable name: S000003B), and rs13280604- allele B (variable 
name: S000004B). No gene variants were found to be significantly associated with 
microalbuminuria in the sibling & twin sample (See Table 4). No gene variants were found to be 
significantly associated with microalbuminuria in the independent sample or the sibling & twin 
sample. Although there was no significant association found between microalbuminuria and gene 
variants, dopamine transporter-DAT1-allele B (variable name: DAT1B) & rs892413 - allele B 
(variable name: S000002B) were approaching significance (See Table 4).  
Hypothesis 2 Results 
Significance in the association between genetic variations and albumin differed between 
male and female respondents. For women within the independent sample population, rs2304297 
- allele A (variable name: S000001A), rs2304297 - allele B (variable name: S000001B), 
rs892413 - allele B (variable name: S000002B), rs4950 - allele A (variable name: S000003A), 
rs4950 - allele B (variable name: S000003B), and rs13280604 - allele A (variable name: 
S000004A) were significantly associated with macroalbumin when compared to male 
respondents. For women in the sibling & twin sample, rs892413 - allele B (variable name: 
S000002B) was found to be significantly associated with macroalbuminuria at p=0.03 (See Table 
5). For microalbumin in the independent sample population, rs2304297 - allele B (variable name: 
S000001B), rs892413 - allele B (variable name: S000002B), and rs4950 - allele A (variable 
name: S000003A) were significantly associated for both male and female respondents, while 
Monoamine Oxidase A-uVNTR-allele A (variable name: MAOA_A), Monoamine Oxidase A-
uVNTR-alB (variable name: MAOA_B), & rs13280604 - allele A (variable name: S000004A) 
were only significantly associated for men.  In both samples collectively, female gender was 
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found to be significantly associated with rs892413 - allele B (variable name: S000002B) and 
rs4950 - allele A (variable name: S000003A) (See Table 6). 
Hypothesis 3 Results 
A logistic model was used to control for variables such as gender, race, BMI, 
hypertension, diabetes, and age. Genetic variants that were found to be significantly associated 
with macroalbumin within the independent sample when controlling for these factors include: 
rs2304297 - allele A (variable name: S000001A) (p=0.005), rs892413 - allele A (variable name: 
S000002A) (p=0.029), and rs4950 - allele B (variable name: S000003B) (p=0.004). No genetic 
variants were found to be significantly associated with macroalbumin in the sibling & twin 
sample when controlling for gender, race, BMI, hypertension, diabetes, and age. For 
microalbumin, Dopamine Transporter-DAT1-allele B (variable name: DAT1B) was found to be 
significantly associated with microalbumin the independent sample group with p=0.007 on loci 
9R (See Table 7). Multicollinearity was assessed between variables, but no multicollinearity was 
found. 
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Chapter 5: Discussion 
 The above results suggest that there may be an association between levels of urine 
albumin in adolescents and genetic variants such as Cytochrome P450 2A6-allele B, rs2304297 - 
allele A, rs2304297 - allele B, rs892413 - allele A, rs892413 - allele B, rs4950 - allele A, rs4950 
- allele B, rs13280604 - allele A, rs13280604 - allele B, Monoamine Oxidase A-uVNTR-allele A 
and Monoamine Oxidase A-uVNTR-allele B. Association in were still significant in rs2304297 - 
allele A, rs892413 - allele A & rs4950 - allele B even after controlling for gender, age, 
hypertension, diabetes, BMI and race in the logistic model. For this study, we reject the null 
hypothesis for hypothesis 1, 2, and 3. These results suggest that there is an association between 
some of the genetic variants analyzed and albuminuria in adolescents. These results also suggest 
there is a significant association between some of the genetic variants when compared by gender 
and control for factors such as race, age, or disease status. While the differences observed among 
this population of respondents was statistically significant, it is important to note that these 
differences are not clinically significant. Those adolescents with higher levels of urine albumin 
should ideally be followed up, within a specific amount of time, with serial albuminuria level 
measurements for definitive diagnosis. For future study, inclusion of race and ethnicity would 
also be important to include and control for in the final model. 
Although there are many limitations to a genetic association study, there are also many 
strengths. For starters, the population used within this study from the National Longitudinal 
Adolescent Health Wave III is large and comprehensively covers people of many different 
demographics. A study that is able to use such a cohort is valid for many populations. Not only 
was it a large population but a large group of adolescents has rarely been studied regarding an 
“old-age” disease such as Chronic Kidney Disease. Another strength of this study includes the 
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analysis of the association of genetic variants with albuminuria in a sample that had similar 
genetic traits because of known familial relationships. This study was able to use a repeated 
measures model in order to efficiently control for familial similarities when analyzing the 
association between genetic variants and albuminuria. This study included two albumin 
measurements, titled macroalbumin and microalbumin, which were collected from the Add 
Health Data committee during Wave III. For replication of this study, it is advised to only use 
one measurement. Both measurements were used to ensure inclusiveness of all the respondents. 
 For future recommendations, results from this study are important in order to increase the 
amount of research being done on Chronic Kidney Disease in younger adults. With the 
increasing rates of childhood obesity, more children are being diagnosed at an earlier age with 
Chronic Kidney Disease. Having a better understanding of the mechanisms of Chronic Kidney 
Disease can help lead early diagnostic & prognostic efforts at a molecular level, as well as 
provide specific therapies and targeted drugs. Melzer & colleagues (2008) say that the direction 
of the relationship between genetic variations and proteins is unknown in many disease 
processes, which may indicate that there may be more pathways involved in CKD than we 
currently know. In order to effectively decrease the risk of chronic kidney disease in adolescents, 
it is imperative for researchers to understand if environmental effects on gene variants that may 
alter protein levels are involved with the disease progression or a result of the disease 
progression (Melzer et al, 2008). 
 For future research, replication of this study could increase knowledge of the interaction 
between several pathways and mechanisms involved in CKD. Future research should follow up 
on the association between albuminuria and the penetrance and frequency of associated alleles 
found in this study. The interaction of genes and their environment will make it easier to guide 
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the implementation of genetic counseling and molecular pharmaceutical design pertaining to 
Chronic Kidney Disease in adolescents. 
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Table 1. Demographic and health characteristics of the Add Health Wave III Study respondents 
Characteristics All Add 
Health 
Respondents  
(n=15,197) 
Sample with 
Urinalysis 
Evaluation 
(n=10,226) 
Sample with 
Macroalbum
in 
measuremen
t (n=6306) 
Sample with 
Microalbumin
uria 
Measurement 
(n=6306) 
Age (yr: 
mean±SD) 
21.9 ± 1.77 21.9 ± 1.77 21.83 ± 1.742 21.83 ± 1.742 
Male (n [%]) 7167 (47.2) 5266 (51.5) 3002 (47.6) 3002 (47.6) 
BMI (kg/m²; 
mean ±SD)¹ 
27.60 ± 9.79 27.76 ± 10.06 29.47 ± 10.59 29.47 ± 10.59 
BMI category 
(kg/m²; n [%]) 
    
       <25 5301 (42.8) 3519 (41.8) 1623 (30.2) 1623 (30.2) 
       25 to <30 3547 (28.7) 2457 (29.2) 1665 (31.0) 1665 (31.0) 
       30 to <35 1730 (14) 1182 (14.1) 979 (18.2) 979 (18.2) 
       ≥35 1795 (14.5) 1252 (14.9) 1109 (20.6) 1109 (20.6) 
Self-Reported 
Conditions (n 
[%]) 
    
      Diabetes 152 (1.0) 103 (1.0) 81 (1.3) 81 (1.3) 
      
Hypertension 
846 (5.6) 590 (5.8) 406 (6.4) 406 (6.4) 
Smoked within 
30 d 
4913 (32) 3400 (33.3) 2014 (31.9) 2014 (31.9) 
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Table 2. Characteristics in respondents with macroalbumin measurement within the genetic sample of Add Health  
Wave III respondents (n=1197*)¹ 
Characteristics Sample with 
Macroalbumin 
measurement (n=76) 
No Macroalbumin 
(n=1121) 
Age (mean ± SD) 21.83 ± 1.872 21.91 ± 1.704 
Male (n [%]) 
Female (n [%]) 
28 (36.8) 
48 (63.2) 
565 (50.4) 
556 (49.6) 
BMI (kg/m²; mean 
±SD)¹ 
30.45 ± 8.7 29.14 ± 11.02 
BMI category (kg/m²; 
n [%]) 
  
       <25 23 (33.3) 304 (27.1) 
       25 to 29.99 17 (22.4) 303 (31.6) 
       30 to 34.99 6 (7.9) 178 (18.6) 
       ≥35 23 (30.3) 173 (18.1) 
Self- Reported 
Conditions (n [%]) 
  
      Diabetes 2 (2.6) 10 (0.9) 
      Hypertension 6 (7.9) 74 (6.6) 
Smoked within 30 
days 
23 (30.3) 344 (30.7) 
*Missing 13 respondents 
¹Excluding pregnant women, ≥75WBC, <50 RBC 
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Table 3. Characteristics in respondents with microalbumin measurement within the genetic sample of Add Health Wave III 
respondents (n=1210)¹ 
Characteristics Sample with 
Microalbumin 
measurement 
(n=48) 
No Microalbumin 
(n=1162) 
Age (mean ± SD) 21.92 ± 1.966 21.89 ± 1.707 
Male (n [%]) 
Female (n [%]) 
16 (33.3) 
32 (66.7) 
580 (49.9) 
582 (50.1) 
BMI (kg/m²; mean 
±SD)¹ 
30.77 ± 8.83 29.13 ± 10.9 
BMI category (kg/m²; 
n [%]) 
  
       <25 12 (27.3) 321 (32.2) 
       25 to 29.99 13 (29.5) 310 (31.2) 
       30 to 34.99 6 (13.6) 179 (18) 
       ≥35 13 (27.1) 184 (18.5) 
Self-Reported 
Conditions (n [%]) 
  
      Diabetes 2 (4.2) 10 (0.9) 
      Hypertension 3 (6.3) 78 (6.7) 
Smoked within 30 d 13 (27.1) 360 (31) 
¹Excluding pregnant women, ≥75WBC, <50 RBC 
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Table 4. Association between genetic variants and respondents with macroalbumin and/or microalbumin measurements 
 
 
 
 
Macroalbumin Microalbumin 
 Independent 
Sample 
Sibling 
&Twin 
Sample 
 Independent 
Sample 
Sibling & 
Twin 
Sample 
Gene 
Variant 
Pearso
n Chi-
Square 
Fisher’s 
Exact 
Test (if 
applicabl
e) 
Repeated 
Measuremen
ts P-value 
 
Gene 
Variant 
Pearso
n Chi-
Square 
Fisher’s 
Exact 
Test (if 
applicabl
e) 
Repeated 
Measureme
nt model p-
value 
 
DAT1A  0.949 - 0.9189 DAT1A  0.634 - 0.9360 
DAT1B  0.792 - 0.9422 DAT1B  0.059 - 0.3491 
DRD4A  0.683 - 0.6346 DRD4A  0.686 - 0.8199 
DRD4B  0.270 - 0.4252 DRD4B  0.618 - 0.8990 
HTTLPR
A  
0.897 1.000 0.6100 HTTLPR
A  
0.450 0.499 0.4229 
HTTLPR
B  
0.514 0.656 0.2471 HTTLPR
B  
0.838 0.772 0.5280 
MAOA_V
A  
0.515 - 0.4428 MAOA_V
A  
0.473 - 0.7811 
MAOA_V
B  
0.393 - 0.6300 MAOA_V
B  
0.168 - 0.6250 
CYP2A6B  0.054 0.075 0.0846 CYP2A6B  0.956 1.000 0.8501 
DRD2A  0.613 1.000 0.7257 DRD2A  0.648 1.000 0.5376 
DRD2B  0.631 0.737 0.6628 DRD2B  0.556 0.657 0.8565 
S000001A  0.003 0.010 0.1412 S000001A  0.153 0.182 0.7545 
S000001B  0.058 0.083 0.1998 S000001B  0.742 0.822 0.5143 
S000002A  0.020 0.033 0.1267 S000002A  0.741 1.000 0.8194 
S000002B  0.031 0.040 0.0675 S000002B  0.264 0.362 0.0595 
S000003A  0.095 0.125 0.5338 S000003A  0.741 0.818 0.2925 
S000003B  0.004 0.011 0.1459 S000003B  0.371 0.325 0.8839 
S000004A  0.135 0.162 0.4644 S000004A  0.860 1.000 0.2991 
S000004B  0.048 0.059 0.2465 S000004B  0.252 0.341 0.6002 
DNA2 0.152 0.235 0.5882 DNA2 0.188 0.313 0.6928 
CONCOR
D 
0.996 - - CONCOR
D  
0.994 - - 
ZYGCHG 0.252 0.598 0.4425 ZYGCHG  0.542 1.000 0.4976 
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Table 5. Association of genetic variants for each gender in those respondents with macroalbumin measurements 
 
 
 
 
 
 
Men Women 
 Independent 
Sample 
Sibling & 
Twins 
Sample 
 Independent 
Sample 
Sibling & 
Twin 
Sample 
Gene 
Variant 
Pearso
n Chi-
Squar
e 
Fisher’s 
Exact 
Test (if 
applicabl
e) 
Repeated 
Measureme
nts p-value  
 
Gene 
Variant 
Pearso
n Chi-
Squar
e 
Fisher’s 
Exact 
Test (if 
applicabl
e) 
Repeated 
Measureme
nts p-value 
DAT1A  0.661 - 0.6601 DAT1A  0.862 - 0.9306 
DAT1B  0.673 - 0.6555 DAT1B  0.657 - - 
DRD4A  0.820 - 0.6760 DRD4A  0.675 - 0.7573 
DRD4B  0.994 - 0.9405 DRD4B  0.068 - 0.1815 
HTTLPR
A  
0.406 0.510 0.9008 HTTLPR
A 
0.940 1.000 0.3714 
HTTLPR
B  
0.959 1.000 0.6244 HTTLPR
B  
0.611 0.778 0.2412 
MAOA_V
A  
0.979 - 0.9148 MAOA_V
A  
0.268 - 0.3666 
MAOA_V
B  
0.979 - 0.9148 MAOA_V
B  
0.181 - 0.5133 
CYP2A6B  0.265 0.309 0.5139 CYP2A6B  0.156 0.162 0.2127 
DRD2A  0.358 1.000 0.8798 DRD2A  1.000 1.000 0.8221 
DRD2B  0.844 1.000 0.6173 DRD2B  0.621 0.692 0.9051 
S000001A  0.541 0.629 0.3152 S000001A  0.002 0.005 0.4535 
S000001B  0.560 0.750 0.8290 S000001B  0.012 0.013 0.1807 
S000002A  0.099 0.124 0.1389 S000002A  0.072 0.106 0.5373 
S000002B  0.683 0.756 0.7721 S000002B  0.006 0.008 0.0366 
S000003A  0.551 0.749 0.3047 S000003A  0.017 0.025 0.1164 
S000003B  0.486 0.621 0.6203 S000003B 0.005 0.010 0.2242 
S000004A  0.602 0.751 0.5674 S000004A  0.047 0.058 0.2167 
S000004B 0.594 0.638 0.8042 S000004B 0.076 0.103 0.3235 
DNA2  0.296 0.540 0.0573 DNA2  - - 0.0518 
CONCOR
D  
0.957  0.9260 CONCOR
D  
- - - 
ZYGCHG  0.658 1.000 0.5022 ZYGCHG  - - 0.6617 
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Table 6. Association of genetic variants for each gender in respondents with microalbumin measurement 
 
 
 
 
Men Women 
 Independent 
Sample 
Sibling & 
Twin 
Sample 
 Independent 
Sample 
Sibling & 
Twin 
Sample 
Gene 
Variant 
Pearso
n Chi-
Square 
Fisher’s 
Exact 
Test (if 
applicabl
e) 
Repeated 
Measureme
nt model p-
value 
Gene 
Variant 
Pearso
n Chi-
Square 
Fisher’s 
Exact 
Test (if 
applicabl
e) 
Repeated 
Measureme
nt model p-
value 
DAT1A  0.990 - 0.9714 DAT1A  0.446 - 0.8461 
DAT1B  0.792 - 0.7703 DAT1B  0.008 - - 
DRD4A 0.608 - 0.7410 DRD4A  0.681 - 0.7610 
DRD4B 0.477 - 0.8897 DRD4B  0.756 - 0.7113 
HTTLPR
A  
0.409 0.668 0.5703 HTTLPR
A  
0.574 0.788 0.7410 
HTTLPR
B  
0.811 1.000 0.6830 HTTLPR
B  
0.520 0.459 0.7502 
MAOA_V
A  
0.000 - 0.2890 MAOA_V
A 
0.623 - 0.5737 
MAOA_V
B  
0.000 - 0.2890 MAOA_V
B  
0.312 - 0.8938 
CYP2A6B  0.617 1.000 0.5553 CYP2A6B  0.775 0.552 0.8534 
DRD2A  0.481 1.000 0.5215 DRD2A  0.944 1.000 0.8803 
DRD2B  0.135 0.220 0.2314 DRD2B  0.090 0.112 0.5208 
S000001A  0.328 1.000 0.9300 S000001A 0.023 0.039 0.8775 
S000001B  0.015 0.030 0.4452 S000001B  0.056 0.096 0.1848 
S000002A  0.342 1.000 0.9076 S000002A  0.784 0.678 0.8902 
S000002B  0.022 0.032 0.5648 S000002B 0.005 0.006 0.0090 
S000003A  0.015 0.030 0.1972 S000003A  0.037 0.047 0.0334 
S000003B  0.344 1.000 0.5634 S000003B  0.113 0.120 0.8969 
S000004A  0.018 0.030 0.3354 S000004A  0.080 0.094 0.0745 
S000004B  0.314 0.599 0.4286 S000004B 0.068 0.079 0.3506 
DNA2    0.1073 DNA2  0.296 0.540 0.5835 
CONCOR
D  
  0.8283 CONCOR
D  
0.957  - 
ZYGCHG    0.5912 ZYGCHG  0.658 1.000 0.2409 
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Table 7. Logistic Regression Model 
 
 
 
 
 
 
 
 
Macroalbumin Microalbumin 
 Independen
t Sample 
Sibling & 
Twins Sample 
 Independen
t Sample 
Sibling & 
Twins Sample 
Gene 
Variant 
Logistic 
Regression 
Repeated 
Measurement
s p-value 
 
Gene 
Variant 
Logistic 
Regression 
Repeated 
Measurement
s p-value 
 
DAT1A  0.828 0.8217 DAT1A  0.087 0.8688 
DAT1B 0.241 0.9361 DAT1B 0.007 0.3449 
DRD4A  0.226 0.5737 DRD4A  0.163 0.9371 
DRD4B  1.000 0.5915 DRD4B  1.000 0.9863 
HTTLPRA  0.735 0.7368 HTTLPRA  0.488 0.4508 
HTTLPRB  0.218 0.2697 HTTLPRB  0.968 0.5074 
MAOA_VA  0.787 0.4835 MAOA_VA  0.644 0.5512 
MAOA_VB  0.782 0.5772 MAOA_VB  0.231 0.5844 
CYP2A6B  0.054 0.0888 CYP2A6B  0.838 0.8343 
DRD2A  0.579 0.5348 DRD2A  0.597 0.3567 
DRD2B  0.913 0.4492 DRD2B  0.752 0.7191 
S000001A  0.005 0.7965 S000001A  0.113 0.6826 
S000001B  0.099 0.7933 S000001B  0.782 0.8451 
S000002A  0.029 0.7473 S000002A  0.731 0.5271 
S000002B  0.089 0.3815 S000002B  0.239 0.1462 
S000003A  0.110 0.8421 S000003A  0.625 0.3397 
S000003B  0.004 0.5191 S000003B  0.487 0.7256 
S000004A  0.170 0.8029 S000004A  0.744 0.5975 
S000004B  0.056 0.7327 S000004B  0.329 0.9347 
DNA2  0.175 0.3206 DNA2  0.983 0.9801 
CONCOR
D  
1.000 - CONCOR
D  
1.000 - 
ZYGCHG  0.999 0.6816 ZYGCHG  0.998 0.3041 
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